Bristol Myers Squibb Co (BMY): Lamberto Andreotti , director of Bristol Myers Squibb Co sold 23,200 shares on Jul 7, 2016. The Insider selling transaction was reported by the company on Jul 11, 2016 to the Securities and Exchange Commission. The shares were sold at $74.65 per share for a total value of $1,727,237.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 30, 2016, Lamberto Andreotti (director) sold 23,200 shares at $72.31 per share price.On Jun 16, 2016, John E Elicker (SVP, Public Affairs & IR) sold 11,820 shares at $72.69 per share price.Also, On May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at $70.79 per share price.On May 17, 2016, Joseph C Caldarella (SVP & Controller) sold 3,519 shares at $72.46 per share price.
Bristol-Myers Squibb Co: On Friday, Jul 8, 2016 heightened volatility was witnessed in Bristol-Myers Squibb Co which led to swings in the share price. The shares opened for trading at $74.29 and hit $75.72 on the upside , eventually ending the session at $75.28, with a gain of 1.62% or 1.2 points. The heightened volatility saw the trading volume jump to 54,28,134 shares. The 52-week high of the share price is $75.72 and the company has a market cap of $125,665 M . The 52-week low of the share price is at $51.82.
Company has been under the radar of several Street Analysts.Bristol-Myers Squibb Co is Initiated by Hilliard Lyons to Neutral. The Rating was issued on May 23, 2016.Bristol-Myers Squibb Co is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 80 from a previous price target of $73 .The Rating was issued on Apr 29, 2016.Bristol-Myers Squibb Co is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 75 from a previous price target of $70 .The Rating was issued on Apr 29, 2016.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.